Holen Sie sich die Stockscreener-App
14.10
1.49%
-0.2101
Überblick
Nachrichten
Preisverlauf
Optionskette
Financials
Warum fällt KVUE?
Forum
Prognose
Dividendenhistorie
Schlusskurs vom Vortag:
$14.31
Offen:
$14.36
24-Stunden-Volumen:
13.38M
Relative Volume:
0.46
Marktkapitalisierung:
$27.05B
Einnahmen:
$15.14B
Nettoeinkommen (Verlust:
$1.42B
KGV:
19.15
EPS:
0.7361
Netto-Cashflow:
$1.63B
1W Leistung:
-6.58%
1M Leistung:
-13.14%
6M Leistung:
-40.27%
1J Leistung:
-38.41%
1-Tages-Spanne:
$14.02
$14.37
1-Wochen-Bereich:
$14.02
$15.33
52-Wochen-Spanne:
$14.02
$25.17
Kenvue Inc Stock (KVUE) Company Profile
Firmenname
Kenvue Inc
Sektor
Telefon
908-874-1200
Adresse
1 KENVUE WAY, SUMMIT
Vergleichen Sie KVUE mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
KVUE
Kenvue Inc
|
14.10 | 27.46B | 15.14B | 1.42B | 1.63B | 0.7361 |
|
PG
Procter Gamble Co
|
149.97 | 347.64B | 84.93B | 16.86B | 14.94B | 6.8506 |
|
UL
Unilever Plc Adr
|
60.72 | 149.49B | 64.99B | 6.71B | 6.53B | 2.4355 |
|
CL
Colgate Palmolive Co
|
76.40 | 61.21B | 20.00B | 3.05B | 3.37B | 3.5578 |
|
KMB
Kimberly Clark Corp
|
119.85 | 38.73B | 18.88B | 2.38B | 2.10B | 7.2549 |
Kenvue Inc Stock (KVUE) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-09-26 | Hochstufung | Rothschild & Co Redburn | Neutral → Buy |
| 2025-04-10 | Eingeleitet | Redburn Atlantic | Neutral |
| 2025-03-24 | Eingeleitet | Evercore ISI | In-line |
| 2025-01-06 | Hochstufung | Piper Sandler | Neutral → Overweight |
| 2024-12-12 | Herabstufung | Deutsche Bank | Buy → Hold |
| 2024-09-24 | Eingeleitet | Jefferies | Buy |
| 2024-09-24 | Herabstufung | RBC Capital Mkts | Outperform → Sector Perform |
| 2024-05-28 | Fortgesetzt | Citigroup | Neutral |
| 2024-04-11 | Eingeleitet | Bernstein | Underperform |
| 2024-04-03 | Eingeleitet | William Blair | Mkt Perform |
| 2024-03-01 | Fortgesetzt | Goldman | Neutral |
| 2023-11-17 | Eingeleitet | Piper Sandler | Neutral |
| 2023-09-11 | Hochstufung | Deutsche Bank | Hold → Buy |
| 2023-09-07 | Eingeleitet | Canaccord Genuity | Buy |
| 2023-09-06 | Eingeleitet | Argus | Hold |
| 2023-08-24 | Hochstufung | Goldman | Neutral → Buy |
| 2023-07-25 | Eingeleitet | Edward Jones | Buy |
| 2023-06-01 | Eingeleitet | HSBC Securities | Hold |
| 2023-05-30 | Eingeleitet | BofA Securities | Buy |
| 2023-05-30 | Eingeleitet | Citigroup | Neutral |
| 2023-05-30 | Eingeleitet | Deutsche Bank | Hold |
| 2023-05-30 | Eingeleitet | Exane BNP Paribas | Neutral |
| 2023-05-30 | Eingeleitet | Goldman | Neutral |
| 2023-05-30 | Eingeleitet | JP Morgan | Overweight |
| 2023-05-30 | Eingeleitet | RBC Capital Mkts | Outperform |
| 2023-05-30 | Eingeleitet | UBS | Neutral |
Alle ansehen
Kenvue Inc Aktie (KVUE) Neueste Nachrichten
Kenvue stock hits 52-week low at 14.04 USD By Investing.com - Investing.com Canada
Jefferies Lowers Kenvue (KVUE) PT to $23, Cites Macroeconomic Headwinds for Consumer Health - Yahoo Finance
Will Kenvue Inc. stock hit analyst forecastsJuly 2025 News Drivers & Consistent Growth Stock Picks - newser.com
The Escalator: Organon, Kenvue, Real Chemistry and more - Medical Marketing and Media
What valuation ratios show for Kenvue Inc. (J4D) stockJuly 2025 Recap & Advanced Technical Signal Analysis - newser.com
Whalen Wealth Management Inc. Acquires New Position in Kenvue Inc. $KVUE - MarketBeat
Tick level data insight on Kenvue Inc. volatilityWeekly Loss Report & Weekly High Return Forecasts - newser.com
How strong is Kenvue Inc. stock earnings growth2025 Performance Recap & AI Powered Buy/Sell Recommendations - newser.com
Does Kenvue (KVUE) Balance Legal Risks and Payouts With a Prudent Capital Allocation Strategy? - simplywall.st
Understanding Kenvue Inc.’s price movementJuly 2025 News Drivers & Consistent Growth Stock Picks - newser.com
Wealthfront Advisers LLC Has $3.41 Million Stock Holdings in Kenvue Inc. $KVUE - MarketBeat
Kenvue (KVUE) Expected to Announce Earnings on Thursday - MarketBeat
Will Kenvue Inc. stock sustain bullish trend into 2025Gap Up & High Yield Stock Recommendations - newser.com
How Kenvue Inc. stock performs in weak economyForecast Cut & Technical Pattern Recognition Alerts - newser.com
Kenvue: Remains A Sell Until The Dividend Is Cut (NYSE:KVUE) - Seeking Alpha
Leading vs lagging indicators on Kenvue Inc. performanceJuly 2025 Patterns & Consistent Profit Alerts - newser.com
Real time scanner hits for Kenvue Inc. explainedEarnings Recap Summary & Consistent Income Trade Recommendations - newser.com
How geopolitical risks impact Kenvue Inc. stock2025 Institutional Moves & Fast Moving Market Watchlists - newser.com
PRODUCTS LIABILITY (DRUGS)—Tex. Dist.: Texas cites twenty-six epidemiological studies in Tylenol marketing suit against Johnson & Johnson, Kenvue - VitalLaw.com
Paxton sues Johnson & Johnson, Kenvue over Tylenol marketing to pregnant women - crossroadstoday.com
US health chief says there is not enough data to show Tylenol causes autism - Reuters
RFK Jr. says Tylenol in pregnancy, autism link is 'very suggestive' - Seeking Alpha
Texas Attorney General Sues Tylenol Makers Over Alleged Autism Risk - Law Commentary
Kenvue: Temporary Headwinds Don't Derail Its Consumer Health Dominance And 5.5% Dividend Yield - Seeking Alpha
Kenvue to tap Jon Halvorson as new chief marketing officer - Medical Marketing and Media
Texas AG sues J&J, Kenvue over Tylenol pregnancy warnings - NJBIZ
Mixed options sentiment in Kenvue Inc with shares down 2.72% - TipRanks
Deutsche Bank Lowers Kenvue (KVUE) PT to $18, Keeps a Hold Rating - Insider Monkey
December 2026 Options Now Available For Kenvue (KVUE) - Nasdaq
Texas Tylenol Lawsuit Accuses J&J of Failing To Warn of Autism Risks - AboutLawsuits.com
Kenvue Hires P&G Exec to Aid Rebound From Tylenol Fallout - Bloomberg.com
The Scoop: Amazon’s layoff memo cuts through public speculation - PR Daily
Texas Sues Tylenol Over Alleged Autism Link - Northwest Signal
Kenvue Keeps Quarterly Dividend at $0.2075 a Share, Payable Nov. 26 to Holders of Record Nov. 12 - MarketScreener
Trump Trade: Texas sues Kenvue, J&J over Tylenol autism risk - TipRanks
Canaccord downgrades Tylenol maker Kenvue as legal risks cloud turnaround - Investing.com
Kenvue Inc. Declares Quarterly Cash Dividend, Payable on November 26, 2025 - MarketScreener
Will Kenvue Inc. stock outperform tech sector in 2025Buy Signal & Breakout Confirmation Trade Signals - newser.com
Mizuho Markets Americas LLC Decreases Stock Holdings in Kenvue Inc. $KVUE - MarketBeat
Canaccord Genuity Downgrades Kenvue to Hold From Buy, Adjusts Price Target to $15 From $26 - MarketScreener
Kenvue downgraded to Hold at Canaccord amid negative headlines - TipRanks
Kenvue Declares Quarterly Cash Dividend - Bluefield Daily Telegraph
Kenvue (KVUE): Assessing Valuation as Legal Risks and Leadership Shifts Raise New Questions - Yahoo Finance
Texas Sues Kenvue, Alleging Deceptive Tylenol Marketing - The Business of Fashion
Teacher Retirement System of Texas Has $18.91 Million Stock Holdings in Kenvue Inc. $KVUE - MarketBeat
D.A. Davidson & CO. Sells 74,699 Shares of Kenvue Inc. $KVUE - MarketBeat
Texas sues Tylenol makers J&J and Kenvue, claiming they hid drug's autism risks | Health | swoknews.com - The Lawton Constitution
Paxton sues Tylenol company over autism claims - Marshall News Messenger
Texas sues Johnson & Johnson over Tylenol autism warningsCHOSUNBIZ - Chosun Biz
Johnson & Johnson, Kenvue slammed with state lawsuit over Tylenol autism claims - Insurance Business America
Texas sues Johnson & Johnson over Tylenol-autism link claims - KEYE
Finanzdaten der Kenvue Inc-Aktie (KVUE)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.03%
1.14%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):